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Abstract
Background—Measurement of adherence to antiretroviral therapy (ART) by patient self-report
is common in resource-limited settings but widely believed to overstate actual adherence. The
extent to which these measures overstate adherence has not been examined among a large patient
population.
Methods—HIV-infected adult patients in Kenya who initiated ART within the past 3 months
were followed for 6 months. Adherence was measured by participants’ self-reports of doses
missed in the past 7 days during monthly clinic visits and by continuous Medication Event
Monitoring System (MEMS) in participants’ pill bottles. Seven-day self-reported adherence was
compared to 7-day MEMS adherence, 30-day MEMS adherence, and adherence more than 90%
during each of the first 6 months.
Results—Self-reported and MEMS adherence measures were linked for 669 participants. Mean
7-day self-reported adherence was 98.7% and mean 7-day MEMS adherence was 86.0%, a
difference of 12.7% (P <0.01). The difference between the two adherence measures increased over
time due to a decline in 7-day MEMS adherence. However, patients with lower MEMS adherence
were in fact more likely to self-report missed doses and the difference between self-reported and
MEMS adherence was similar for each number of self-reported missed doses. When analysis was
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limited to patients who reported rarely or never removing multiple doses at the same time, mean
difference was 10.5% (P <0.01).
Conclusion—There is a sizable and significant difference between self-reported and MEMS
adherence. However, a strong relationship between the measures suggests that self-reported
adherence is informative for clinical monitoring and program evaluation.
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Introduction
Consistent adherence to HIV antiretroviral therapy (ART) is necessary for viral suppression,
prevention of drug resistance, and delaying disease progression [1-3]. Although adherence in
resource-limited settings (RLSs) is generally sufficient to achieve viral suppression, various
structural and behavioral factors can lead to low adherence and treatment failure on long-
term therapy [4-8]. Adherence monitoring is necessary to identify individuals needing
intervention, especially in the absence of virologic monitoring.
Patients’ self-reports of missed doses have been used extensively because they are
inexpensive, easy to implement, and can identify patient-specific barriers to adherence [8,9].
Self-reported adherence has seldom been compared to more objective methods for
measuring adherence such as electronic monitoring with Medication Event Monitoring
System (MEMS) bottle caps. Most studies using MEMS caps have been conducted in North
America and have generally found that self-reports overestimate adherence and are only
modestly associated with MEMS estimates [1,8,10-12].
We compared 7-day self-reported adherence to several MEMS adherence measures among
patients receiving ART in Kenya in order to determine the strength of association and
difference between the two measures.
Methods
Setting
This study relied on data collected as part of a randomized trial of text messages to improve
adherence to ART conducted at the Chulaimbo Rural Health Center (CRHC), a government-
run health facility in Nyanza Province, Kenya where the USAID-Academic Model
Providing Access to Healthcare (AMPATH) Partnership provides comprehensive HIV care
at no cost to patients [13].
Study population and procedures
HIV-infected adults initiating ART at CRHC were recruited from June 2007 until August
2008. Patients were eligible for the study if they were older than 18 years and had initiated
ART less than 3 months prior to enrollment. As the primary goal of the study was to
evaluate the effect of text messages on adherence, patients were informed that they would
receive a mobile phone and that some would be randomly selected to receive daily or
weekly text messages encouraging ART adherence. The study was approved by the
Institutional Research Ethics Committee of Moi University School of Medicine and the
Institutional Review Boards of Georgetown University and the University of North Carolina
at Chapel Hill.
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Pharmacy staff transferred one of the participants’ three antiretroviral medications
(lamivudine) to a bottle with a MEMS cap (Aardex Group, Switzerland) that recorded the
date and time of each bottle opening. Participants were informed about the function of
MEMS caps during the informed consent process, and they were instructed to open the
bottles only when ingesting.
Participants returned every month for appointments with AMPATH clinical officers in
accordance with standard clinic procedures. Study staff downloaded MEMS data and
obtained patients’ reports of the number of doses that they missed in the past 7 days.
Adherence measures
Data from the return visit questionnaires were used to calculate 7-day self-reported
adherence at each clinic visit [(1–number of missed doses/14)×100]. The MEMS data were
used to calculate three adherence measures for each return visit:
1. Seven-day MEMS adherence, defined as the percentage of prescribed doses taken
during the past 7 days (100 × number of openings in past 7 days/14);
2. Thirty-day MEMS adherence, defined as the percentage of prescribed doses taken
during the past 30 days (100 × number of openings in past 30 days/60).
3. Binary indicator of whether 7-day MEMS adherence exceeded 90%, a standard for
excellent adherence that uniformly achieves viral suppression on nonnucleoside
reverse transcriptase inhibitor therapy [14].
The number of daily bottle openingswas truncated to 2 in order to avoid overstating of
adherence. Adherence data were analyzed over the first 6 months after recruitment.
Statistical analyses
For each of the first 6 months of the study, a mean comparison t-test was performed to
determine whether the difference between 7-day self-reported adherence and 7-day or 30-
day MEMS adherence was significantly different from zero. This test was also conducted to
compare adherence measures during the first 6 months combined.
Some participants reported removing multiple doses at the same time, perhaps to take doses
at a later time when they would not have the bottle with them. As this can artificially lower
MEMS adherence and is considered a limitation of MEMS measures [15], we also examined
MEMS adherence among participants who did not report removing multiple doses at the
same time.
Results
A total of 720 patients were enrolled. MEMS data were obtained from 717 participants.
Mean duration of follow-up was 6.2 months [interquartile range (IQR) 3–9 months]. During
the first 6 months, 2797 return visit questionnaires were completed among 669 participants
and matched to MEMS data. Data entry errors were the most common reason for not
matching return visit questionnaires to MEMS data. Participants whose self-reported and
MEMS data were not matched had similar age, sex, and education as participants whose
data were matched.
Among the 669 participants, 69% were women and the mean age was 36 years. Thirty-one
percent were married and 40% widowed. More than half the participants (56%) had
completed at least primary school and 22% had completed secondary school. The mean one-
way travel time from home to clinic was 1.47 h (IQR 0.75–2).
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Self-reported number of missed doses and corresponding Medication Event Monitoring
System adherence
Table 1 tabulates the number of self-reported missed doses in the first 6 months of the study
and the corresponding MEMS adherence. In 2541 (90.8%) return visit interviews,
participants reported 0 missed doses during the past 7 days. The mean 7-day MEMS
adherence corresponding to each number of self-reported missed doses indicates that
participants who reported greater numbers of missed doses also had lower MEMS
adherence; and MEMS adherence was found to be 12–14% lower than self-reported
adherence. The proportion with 7-day MEMS adherence more than 90% was also associated
with self-reported adherence, as this was lower for those who reported greater numbers of
missed doses. Among those who reported no missed doses during the past 7 days, mean 7-
day MEMS adherence was 87% and the proportion with MEMS adherence more than 90%
was 0.73. In comparison, among those who reported one, two, and three missed doses during
the past 7 days, mean 7-day MEMS adherence was 79, 74, and 65% respectively, whereas
the proportion with MEMS adherence more than 90% was 0.51, 0.28, and 0.39, respectively.
Comparison of self-reported and Medication Event Monitoring System adherence by
month of follow-up
Seven-day self-reported adherence was high in each month, with a mean of 98.7% over 6
months. MEMS data indicated significantly lower adherence. Mean 7-day MEMS adherence
over 6 months was 86.0%, or 12.7% lower than 7-day self-reported adherence (P <0.01).
The mean difference between the 7-day self-reported and MEMS adherence measures was
similar in the study’s intervention and control groups (12.6 and 12.9%, P ¼0.74). Thirty-day
MEMS adherence was similar to 7-day MEMS adherence and 12.5% lower than 7-day self-
reported adherence (P <0.01). The proportion with adherence more than 90% was also lower
than what would be expected based on self-reported adherence. Sex, age, school attainment,
household size, marital status, alcohol use, and disclosure to somebody in the household
were not significantly associated with the difference between self-reported and MEMS
adherence.
There was a statistically significant difference between self-reported and MEMS adherence
in each month of follow-up (P <0.01) that increased over time due to a decline in MEMS
adherence. The difference between 7-day self-reported adherence and 7-day MEMS
adherence was 9.8% at the first month of follow-up and rose to 13.4% at 6 months; a linear
trend was statistically significant (P <0.01). The proportion with 7-day MEMS adherence
more than 90% also declined over time, from 0.76 to 0.68.
Participants reported having removed multiple doses at the same time in 9.9% (2797) of the
return visits. In visits during which multiple dose removal was not reported, the discrepancy
between 7-day self-reported adherence and 7-day MEMS adherence was smaller than those
reported in Table 2 but remained statistically significant (mean difference = 10.5%; P <0.01;
results not reported).
Discussion
Our findings show that although patient-reported measures of adherence are consistently
higher than MEMS adherence, there is a significant association between the measures. Self-
reported adherence exceeded MEMS adherence by 12.7%, but patients with lower MEMS
adherence were in fact more likely to self-report missed doses. Importantly, the difference
between the two adherence measures was similar across a range of self-reported adherence;
this difference did not get larger for patients with low self-reported adherence. Self-reports
of having removed multiple doses at the same time were also consistent with the MEMS
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data; the difference between self-reported and MEMS adherence was narrowed to 10.5%
among participants who did not remove multiple doses. These findings suggest that although
self-reports are an imperfect measure of adherence, they can convey useful information.
Three other findings also warrant discussion. First, the finding that self-reported adherence
exceeds MEMS adherence is consistent with several other studies in both resource-rich and
resource-limited settings [8,9,12,16], but the size of the difference has not previously been
estimated among a large cohort of patients in sub-Saharan Africa. The difference between
the two measures is significantly smaller than the 25–30% difference reported in resource-
rich settings [9,16] and may be related to the high level of adherence observed in this study.
Second, although self-reported adherence showed minimal decline over time, 7-day and 30-
day MEMS adherence showed larger declines, from 89.7 to 83.8% between month 1 and 6
in the case of 30-day adherence. The decline in adherence over time has been attributed to
factors including pill fatigue, the plateau of health benefits, and accumulating long-term
side-effects [4,6,17]. Our findings imply that self-reports may not detect these declines. As
declines in adherence in the long-term may contribute to virologic failure, there is a need for
greater adherence monitoring and adherence support interventions. Finally, the inability to
find predictors of the difference between self-reported adherence and the more objective
MEMS measure of adherence suggests that it is not easy to identify which patients are likely
to overestimate adherence.
Several limitations of this study merit consideration. First, the findings apply to one study
site and may not be generalizable to other patient populations. The large sample, however,
may make the findings more comparable to other such sites than existing data. Second, we
do not compare MEMS adherence to other adherence measures that may be relatively easier
to implement and are also common in RLS, such as pharmacy refill [18]. Nonetheless,
quantifying the difference between self-reported and MEMS adherence provides a better
sense of how to interpret one of the most widely used adherence measures in RLS. A third
limitation is that we lacked clinical characteristics and are, therefore, unable to compare
them to the adherence measures.
Conclusion
In conclusion, we find that although self-reported adherence consistently overestimates
adherence, it does contain useful adherence information because the overestimation can be
quantified over time. Self-reported adherence measures combined with other objective and
feasible measures like those based on pharmacy claims data [18] may be a useful strategy
for identifying patients in need of additional adherence support.
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